シクロスポリン薬剤市場：用途別、剤形別、タイプ別、性別、年齢層別、エンドユーザー別、地域別

シクロスポリン薬剤市場は、2025年には43億7,000万米ドルと推定され、2032年には63億3,000万米ドルに達すると予測され、2025～2032年までの年間平均成長率（CAGR）は5.4%で成長すると予測されます。

世界のシクロスポリン薬剤市場は、1970年代の発見以来、移植医療と自己免疫疾患管理に革命をもたらしたこの強力なカルシニューリン阻害剤の製剤を含む、免疫抑制治療における重要なセグメントです。シクロスポリンはTolypocladium inflatumという真菌に由来する環状ポリペプチドで、T細胞の活性化と増殖を選択的に阻害することにより機能し、移植を受けた患者の臓器拒絶反応の予防や、関節リウマチ、乾癬、炎症性腸疾患などの様々な自己免疫疾患の治療に不可欠なものとなっています。この市場には、経口カプセル剤、経口溶液剤、静脈注射剤など複数の製剤があり、治療濃度の異なるブランド品とジェネリック品の両方が販売されています。世界中のヘルスケアシステムが移植術を進歩させ、自己免疫疾患の治療選択肢を拡大し続けている中、シクロスポリン薬剤市場は、より新しい免疫抑制剤の出現にもかかわらず、その重要性を維持しています。市場の進化は、投与レジメンの最適化、バイオアベイラビリティを向上させた製剤の改良、副作用を最小限に抑えながら治療効果を最大化する併用療法に関する継続的な研究によって特徴付けられ、シクロスポリンは現代の免疫抑制治療プロトコルの要となる治療として位置付けられています。

市場力学

世界のシクロスポリン薬剤市場は、自己免疫疾患の有病率の上昇、世界の臓器移植の増加、ヘルスケア専門家や患者の免疫抑制療法に対する意識の高まりなど、いくつかの主要促進要因に後押しされています。自己免疫疾患や移植を必要とする臓器不全に罹患しやすい高齢者の拡大は、移植手術技術の進歩や患者の生存率の向上と並んで、長期的な免疫抑制療法に対する持続的な需要を促進し、市場の成長に大きく寄与しています。さらに、臓器移植を必要とすることが多い糖尿病や心血管障害などの慢性疾患の発生率が上昇していることも、市場の拡大をさらに後押ししています。しかし、市場は、安全性プロファイルに優れる可能性のある代替免疫抑制剤の利用可能性、医薬品承認とモニタリングに関する厳しい規制要件、新興市場での利用を制限する可能性のあるシクロスポリン治療の高額費用など、大きな抑制要因に直面しています。また、シクロスポリンは治療域が狭く、頻繁な薬剤モニタリングが必要であるため、医療従事者や患者にとってさらなる課題となる一方、腎毒性、肝毒性、感染リスクの上昇などの副作用の可能性があるため、患者集団によっては使用が制限されることもあります。バイオアベイラビリティの向上と副作用の軽減を実現した新規シクロスポリン製剤の開発、ヘルスケアインフラが整備されつつある市場への進出、希少な自己免疫疾患の治療への応用の可能性などから、大きなビジネス機会が生まれています。個別化医療と薬理ゲノミクスへの注目の高まりは、シクロスポリンの投与戦略を最適化する機会を提供する一方、併用療法と新たな治療適応に関する継続的な研究は、市場の潜在的な範囲と臨床的有用性を拡大し続けています。

本調査の主要特徴

• 本レポートでは、世界のシクロスポリン薬剤市場を詳細に分析し、2024年を基準年とした予測期間（2025～2032年）の市場規模（10億米ドル）と年間平均成長率（CAGR%）を掲載しています。
• また、さまざまなセグメントにわたる潜在的な収益機会を明らかにし、この市場の魅力的な投資提案のマトリックスについて説明しています。
• また、市場促進要因、抑制要因、機会、新製品の上市や承認、市場動向、地域による展望、主要企業が採用する競争戦略などに関する重要な考察も提供しています。
• 企業ハイライト、製品ポートフォリオ、主要なハイライト、財務実績、戦略などのパラメータに基づいて、世界のシクロスポリン薬剤市場の主要企業をプロファイルしています。
• 本レポートから洞察により、マーケティング担当者や企業の経営陣は、将来の製品発売、タイプアップ、市場拡大、マーケティング戦術に関する情報に基づいた意思決定を行うことができます。
• 世界のシクロスポリン薬剤市場レポートは、投資家、サプライヤー、製品メーカー、流通業者、新規参入者、財務アナリストなど、この産業の様々な利害関係者に対応しています。
• 利害関係者は、世界のシクロスポリン薬剤市場分析に使用される様々な戦略マトリックスを通じて、意思決定を容易にすることができます。

目次

第1章 調査の目的と前提条件

• 調査目的
• 前提条件
• 略語

第2章 市場展望

• レポートの説明
  • 市場の定義と範囲
• エグゼクティブサマリー

第3章 市場力学、規制、動向分析

• 市場力学
• 促進要因
• 抑制要因
• 機会
• 影響分析
• 規制シナリオ
• 製品の発売/承認
• PEST分析
• ポーター分析
• 合併と買収のシナリオ
• 産業動向

第4章 世界のシクロスポリン薬剤市場、用途別、2020～2032年

• イントロダクション
• 臓器移植拒絶反応予防
• 自己免疫疾患
• 眼疾患
• 皮膚疾患
• その他

第5章 世界のシクロスポリン薬剤市場、剤形別、2020～2032年

• イントロダクション
• カプセル
• 錠剤
• 経口溶液
• 静脈内溶液
• 局所溶液
• 目薬

第6章 世界のシクロスポリン薬剤市場、タイプ別、2020～2032年

• イントロダクション
• ブランド
• ジェネリック

第7章 世界のシクロスポリン薬剤市場、性別、2020～2032年

• イントロダクション
• 男性
• 女性

第8章 世界のシクロスポリン薬剤市場、年齢層別、2020～2032年

• イントロダクション
• 小児
• 成人
• 高齢者

第9章 世界のシクロスポリン薬剤市場、エンドユーザー別、2020～2032年

• イントロダクション
• 病院
• 専門クリニック
• 外来手術センターまたは移植センター
• 在宅ケア
• 学術研究機関
• その他（専門薬局）

第10章 世界のシクロスポリン薬剤市場、地域別、2020～2032年

• イントロダクション
• 北米
  • 米国
  • カナダ
• ラテンアメリカ
  • ブラジル
  • アルゼンチン
  • メキシコ
  • その他のラテンアメリカ
• 欧州
  • ドイツ
  • 英国
  • スペイン
  • フランス
  • イタリア
  • ロシア
  • その他の欧州
• アジア太平洋
  • 中国
  • インド
  • 日本
  • オーストラリア
  • 韓国
  • ASEAN諸国
  • その他のアジア太平洋
• 中東
  • GCC諸国
  • イスラエル
  • その他の中東
• アフリカ
  • 南アフリカ
  • 北アフリカ
  • 中央アフリカ

第11章 競合情勢

• Novartis AG
• Teva Pharmaceutical
• Sun Pharmaceuticals
• Mylan（Viatris）
• Hikma Pharmaceuticals
• Glenmark Pharmaceuticals
• Zydus Lifesciences
• Lupin Limited
• Cipla Ltd
• Santen Pharmaceutical
• Amneal Pharmaceuticals
• Endo International
• Strides Pharma
• Panacea BIoTec

第12章 アナリストの推奨事項

• 機会
• 一貫型機会マップ

第13章 参考文献と調査手法

• 参考文献
• 調査手法
• 出版社について

Cyclosporine Drug Market is estimated to be valued at USD 4.37 Bn in 2025 and is expected to reach USD 6.33 Bn by 2032, growing at a compound annual growth rate (CAGR) of 5.4% from 2025 to 2032.

The global cyclosporine drug market represents a critical segment within the immunosuppressive therapeutics landscape, encompassing pharmaceutical formulations of this potent calcineurin inhibitor that has revolutionized transplant medicine and autoimmune disease management since its discovery in the 1970s. Cyclosporine, a cyclic polypeptide derived from the fungus Tolypocladium inflatum, functions by selectively inhibiting T-cell activation and proliferation, making it indispensable for preventing organ rejection in transplant recipients and treating various autoimmune conditions including rheumatoid arthritis, psoriasis, and inflammatory bowel disease. The market encompasses multiple formulations including oral capsules, oral solutions, and intravenous preparations, with both branded and generic versions available across different therapeutic concentrations. As healthcare systems worldwide continue to advance transplantation procedures and expand treatment options for autoimmune disorders, the cyclosporine drug market maintains its significance despite the emergence of newer immunosuppressive agents. The market's evolution is characterized by ongoing research into optimized dosing regimens, improved formulations with enhanced bioavailability, and combination therapies that maximize therapeutic efficacy while minimizing adverse effects, positioning cyclosporine as a cornerstone therapy in modern immunosuppressive treatment protocols.

Market Dynamics:

The global cyclosporine drug market is propelled by several key drivers, including the rising prevalence of autoimmune diseases, increasing organ transplantation procedures worldwide, and growing awareness of immunosuppressive therapies among healthcare professionals and patients. The expanding geriatric population, which is more susceptible to autoimmune conditions and organ failure requiring transplantation, significantly contributes to market growth, alongside advancements in transplant surgery techniques and improved patient survival rates that drive sustained demand for long-term immunosuppressive therapy. Additionally, the increasing incidence of chronic diseases such as diabetes and cardiovascular disorders, which often necessitate organ transplantation, further fuels market expansion. However, the market faces substantial restraints including the availability of alternative immunosuppressive agents with potentially superior safety profiles, stringent regulatory requirements for drug approval and monitoring, and the high cost of cyclosporine therapy that may limit accessibility in emerging markets. The drug's narrow therapeutic window and requirement for frequent therapeutic drug monitoring create additional challenges for healthcare providers and patients, while potential side effects including nephrotoxicity, hepatotoxicity, and increased infection risk may limit its use in certain patient populations. Nevertheless, significant opportunities emerge from the development of novel cyclosporine formulations with improved bioavailability and reduced side effects, expansion into emerging markets with growing healthcare infrastructure, and potential applications in treating rare autoimmune conditions. The increasing focus on personalized medicine and pharmacogenomics presents opportunities for optimized cyclosporine dosing strategies, while ongoing research into combination therapies and new therapeutic indications continues to expand the market's potential scope and clinical utility.

Key Features of the Study:

• This report provides in-depth analysis of the global cyclosporine drug market, and provides market size (USD Bn) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global cyclosporine drug market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study include Novartis AG, Teva Pharmaceutical, Sun Pharmaceuticals, Mylan (Viatris), Hikma Pharmaceuticals, Glenmark Pharmaceuticals, Zydus Lifesciences, Lupin Limited, Cipla Ltd, Santen Pharmaceutical, Amneal Pharmaceuticals, Endo International, Strides Pharma, ans Panacea Biotec.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• The global cyclosporine drug market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global cyclosporine drug market

Market Segmentation

• Application Insights (Revenue, USD Bn, 2020 - 2032)
  • Organ Transplant Rejection Prophylaxis
  • Kidney Transplant
  • Liver Transplant
  • Heart Transplant
  • Lung Transplant
  • Autoimmune Disorders
  • Rheumatoid Arthritis
  • Psoriasis
  • Myasthenia Gravis
  • Crohn's Disease
  • Nephrotic Syndrome
  • Ophthalmic Disorders
  • Dry Eye Disease
  • Vernal Keratoconjunctivitis
  • Dermatological Disorders
  • Severe Atopic Dermatitis
  • Other Severe Inflammatory Skin Conditions
  • Other Uses
• Formulation Insights (Revenue, USD Bn, 2020 - 2032)
  • Capsules
  • Tablets
  • Oral Solution
  • Intravenous Solution
  • Topical Solution
  • Eye Drops
• Type Insights (Revenue, USD Bn, 2020 - 2032)
  • Brand
  • Generic
• Gender Insights (Revenue, USD Bn, 2020 - 2032)
  • Male
  • Female
• Age Group Insights (Revenue, USD Bn, 2020 - 2032)
  • Pediatric
  • Adult
  • Geriatric
• End User Insights (Revenue, USD Bn, 2020 - 2032)
  • Hospitals
  • Specialty Clinics
  • Ambulatory Surgical Centers or Transplant Centers
  • Homecare Settings
  • Academic & Research Institutions
  • Others (Specialty Pharmacies)
• Regional Insights (Revenue, USD Bn, 2020 - 2032)
  • North America
  • U.S.
  • Canada
  • Latin America
  • Brazil
  • Argentina
  • Mexico
  • Rest of Latin America
  • Europe
  • Germany
  • U.K.
  • Spain
  • France
  • Italy
  • Russia
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
  • Middle East
  • GCC Countries
  • Israel
  • Rest of Middle East
  • Africa
  • South Africa
  • North Africa
  • Central Africa
• Key Players Insights
  • Novartis AG
  • Teva Pharmaceutical
  • Sun Pharmaceuticals
  • Mylan (Viatris)
  • Hikma Pharmaceuticals
  • Glenmark Pharmaceuticals
  • Zydus Lifesciences
  • Lupin Limited
  • Cipla Ltd
  • Santen Pharmaceutical
  • Amneal Pharmaceuticals
  • Endo International
  • Strides Pharma
  • Panacea Biotec

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Global Cyclosporine Drug Market, By Application
  • Global Cyclosporine Drug Market, By Formulation
  • Global Cyclosporine Drug Market, By Type
  • Global Cyclosporine Drug Market, By Gender
  • Global Cyclosporine Drug Market, By Age Group
  • Global Cyclosporine Drug Market, By End User
  • Global Cyclosporine Drug Market, By Region

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
• Driver
• Restraint
• Opportunity
• Impact Analysis
• Key Developments
• Regulatory Scenario
• Product Launches/Approvals
• PEST Analysis
• PORTER's Analysis
• Merger and Acquisition Scenario
• Industry Trends

4. Global Cyclosporine Drug Market, By Application, 2020-2032, (USD Bn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Organ Transplant Rejection Prophylaxis
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
    • Kidney Transplant
    • Liver Transplant
    • Heart Transplant
    • Lung Transplant
• Autoimmune Disorders
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
    • Rheumatoid Arthritis
    • Psoriasis
    • Myasthenia Gravis
    • Crohn's Disease
    • Nephrotic Syndrome
• Ophthalmic Disorders
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
    • Dry Eye Disease
    • Vernal Keratoconjunctivitis
• Dermatological Disorders
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
    • Severe Atopic Dermatitis
    • Other Severe Inflammatory Skin Conditions
• Other Uses
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

5. Global Cyclosporine Drug Market, By Formulation, 2020-2032, (USD Bn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Capsules
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Tablets
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Oral Solution
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Intravenous Solution
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Topical Solution
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Eye Drops
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

6. Global Cyclosporine Drug Market, By Type, 2020-2032, (USD Bn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Brand
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Generic
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

7. Global Cyclosporine Drug Market, By Gender, 2020-2032, (USD Bn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Male
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Female
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

8. Global Cyclosporine Drug Market, By Age Group, 2020-2032, (USD Bn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Pediatric
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Adult
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Geriatric
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

9. Global Cyclosporine Drug Market, By End User, 2020-2032, (USD Bn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Hospitals
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Specialty Clinics
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Ambulatory Surgical Centers or Transplant Centers
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Homecare Settings
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Academic & Research Institutions
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Others (Specialty Pharmacies)
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

10. Global Cyclosporine Drug Market, By Region, 2020 - 2032, Value (USD Bn)

• Introduction
  • Market Share (%) Analysis, 2025, 2028 & 2032, Value (USD Bn)
  • Market Y-o-Y Growth Analysis (%), 2021 - 2032, Value (USD Bn)
  • Regional Trends
• North America
  • Introduction
  • Market Size and Forecast, By Application, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Formulation, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Type, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Gender, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
    • U.S.
    • Canada
• Latin America
  • Introduction
  • Market Size and Forecast, By Application, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Formulation, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Type, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Gender, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
    • Brazil
    • Argentina
    • Mexico
    • Rest of Latin America
• Europe
  • Introduction
  • Market Size and Forecast, By Application, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Formulation, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Type, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Gender, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
    • Germany
    • U.K.
    • Spain
    • France
    • Italy
    • Russia
    • Rest of Europe
• Asia Pacific
  • Introduction
  • Market Size and Forecast, By Application, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Formulation, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Type, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Gender, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
• Middle East
  • Introduction
  • Market Size and Forecast, By Application, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Formulation, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Type, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Gender, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
    • GCC Countries
    • Israel
    • Rest of Middle East
• Africa
  • Introduction
  • Market Size and Forecast, By Application, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Formulation, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Type, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Gender, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Country/Region, 2020 - 2032, Value (USD Bn)
    • South Africa
    • North Africa
    • Central Africa

11. Competitive Landscape

• Novartis AG
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Teva Pharmaceutical
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Sun Pharmaceuticals
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Mylan (Viatris)
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Hikma Pharmaceuticals
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Glenmark Pharmaceuticals
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Zydus Lifesciences
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Lupin Limited
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Cipla Ltd
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Santen Pharmaceutical
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Amneal Pharmaceuticals
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Endo International
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Strides Pharma
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Panacea Biotec
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies

12. Analyst Recommendations

• Wheel of Fortune
• Analyst View
• Coherent Opportunity Map

13. References and Research Methodology

• References
• Research Methodology
• About us